The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

By sjmartinez • April 27, 2025

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis. 2025 Apr 5:104036. doi: 10.1016/j.numecd.2025.104036. Epub ahead of print. PMID: 40287313.

Tags: ASCVD, atherosclerotic cardiovascular disease, CAC, Cardiology/Epi, cardiovascular disease, Computed Tomography Angiography, coronary artery calcium, CTA, CVD, General Internal Medicine, GLP1 receptor agonists, Harbor UCLA, HCC, Hepatocellular carcinoma, MASH, MASLD, Metabolic dysfunction-associated Steatohepatitis, Metabolic dysfunction-associated steatotic liver disease, Publications, randomized trial, Resident, semaglutide

Related Posts

Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review

Leiva O, Liu O, Kanelidis A, Swat S, Gozdecki L, Belkin M, Grinstein J, Kalantari S, Kim G, DeCara J, Chung B, Patel A, Odenike[...]

Access to digital health technologies: personalized framework and global perspectives

Narayan SM, Chung MK, Adedinsewo D, Brant LCC, Davis LL, Duncker D, Hall JL, Han JK, Lam CSP, Lewis E, Loscalzo J, Márquez MF, Rahimzadeh[...]

Detecting structural heart disease from electrocardiograms using AI

Poterucha TJ, Jing L, Ricart RP, Adjei-Mosi M, Finer J, Hartzel D, Kelsey C, Long A, Rocha D, Ruhl JA, vanMaanen D, Probst MA, Daniels[...]